New strategies for lowering the costs of antiretroviral treatment and care for people with HIV/AIDS in the United Kingdom

ClinicoEconomics and Outcomes Research

Volumn 4, Issue 1, 2012, Pages 193-200

  Gazzard, Brian ^a   Moecklinghoff, Christiane ^b   Hill, Andrew ^c  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^b Janssen   (Germany)

^c UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Darunavir ritonavir monotherapy; Generics; Health economics; Non nucleoside reverse transcriptase inhibitors; Nucleoside analogs

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR PLUS RITONAVIR; DARUNAVIR PLUS RITONAVIR; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; ETRAVIRINE; GENERIC DRUG; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; MARAVIROC; NEVIRAPINE; RALTEGRAVIR; RITONAVIR PLUS SAQUINAVIR; TENOFOVIR; ZIDOVUDINE;

BLOOD TOXICITY; BUDGET; CD4 LYMPHOCYTE COUNT; COST BENEFIT ANALYSIS; COST CONTROL; DIAGNOSTIC TEST; DRUG COST; DRUG EFFICACY; HEALTH CARE ACCESS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEDICAL ETHICS; PATIENT CARE; PRACTICE GUIDELINE; REVIEW; UNITED KINGDOM; VIRUS LOAD;

EID: 84864320225     PISSN: None     EISSN: 11786981     Source Type: Journal    
DOI: None     Document Type: Review

References (33)

1. House of Lords. No vaccine, no cure: HIV and AIDS in the United Kingdom. Available from: http://www.publications.parliament.uk/pa/ld201012/ldselect/ldaids/188/188.pdf. Accessed May 30, 2012.
2. Health Protection Agency. HIV in the United Kingdom: 2011 report. Available from: http://www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/1317131685847. Accessed May 30, 2012.
3. British HIV Association. BHIVA guidelines for the treatment of adult HIV-1 infected adults with antiretroviral therapy 2012. Available from: http://www.bhiva.org/documents/Guidelines/Treatment%20Guidelines/2012/formatted__ART_guidelines_04022012_v3_IW.pdf. Accessed May 30, 2012.
4. European AIDS Clinical Society. Guidelines for the clinical management of HIV infected adults in Europe. Available from: http://www.europeanaidsclinicalsociety.org/index.php?option=com_content&view=article&id=59&Itemid=41. Accessed May 30, 2012.
5. Department of Health and Human Sciences. AIDS info. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Available at: http://aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-treatment-guidelines/37/whats-new-in-the-guidelines-. Accessed May 30, 2012.
6. Nakagawa F, Lodwick R, Smith C, et al. Projected life expectancy of people with HIV according to timing of diagnosis. AIDS. 2012;26(3):335-343.
7. Cohen M, Chen Y, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365(6):493-505.
8. AIDS Info. Clinical Guidelines Portal. Available at: http://aidsinfo.nih.gov/Guidelines/GuidelineDetail.aspx?GuidelineID=387&ClassID=4. Accessed October 21, 2011.
9. Olsen CH, Gatell J, Ledergerber B, et al. Risk of AIDS and death at given HIV-RNA and CD4 cell counts, in relation to specific antiretroviral drugs in the regimen. AIDS. 2005;19(3):319-330.
10. The PLATO Collaboration 2004. Predictors of trend in CD4 positive T-cell count and mortality among HIV-1 infected individuals with virological failure to all three antiretroviral drug classes. Lancet. 2004;364(9492):51-62.
11. Mee P, Fielding K, Charalambous S, Churchyard GJ, Grant AD. Evaluation of the WHO criteria for antiretroviral treatment failure among adults in South Africa. AIDS. 2008;22(15):1971-1977.
12. Reynolds S, Kakigozi G, Newell K, et al. Failure of immunologic criteria to appropriately identify antiretroviral treatment failure in Uganda. AIDS. 2009;23(6):697-700.
13. Mocroft A, Phillips A, Gatell J, et al. Normalisation of CD4 counts in patients with HIV-1 infection and maximum virological suppression who are taking combination antiretroviral therapy: an observational cohort study. Lancet. 2007;370(3585):407-413.
14. Phillips A, Youle M, Lampe F, et al. CD4 cell count changes in individuals with counts above 500 cells/mm3 and viral loads below 50 copies/mL on antiretroviral therapy. AIDS. 2002;16(7):1073-1075.
15. Chilton D, Neuhaus J, Palfreeman A. Utility of CD4 count monitoring in patients on HAART who maintain viral load suppression - experience from the VS arm of the SMART study. Abstract O21 presented at the Fourteenth British HIVAssociation Conference, April 23-25, 2008, Belfast, Ireland.
16. The UK Collaborative Group on HIV Drug Resistance, UK CHIC Study Group. Long term probability of detection of HIV-1 drug resistance after starting antiretroviral therapy in routine clinical practice. AIDS. 2005;19(5):487-494.
17. Medecins Sans Frontieres. Untangling the web of antiretroviral price reductions: a pricing guide for the purchase of ARVs for developing countries. 12th ed, prepublication price analysis, July 2009. Available at: http://www.msfaccess.org/content/untangling-web-antiretroviral-price-reductions-14th-edition.
18. British National Formulary. BNF 57, March 2009. Available from: http://www.esoph.org/af/books/BNF%2057.pdf. Accessed May 30, 2012.
19. United Pharmacies. Cost of generic 3TC and ZDV in the UK (60 tablets). Available from: http://www.unitedpharmacies-uk.com/3TC_150mg_60_Tablets_p_891.html. Accessed May 30, 2012.
20. Grupo de Estudio de SIDA Expert Panel and the National AIDS Plan. GESIDA consensus document/Spanish AIDS plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection. Spanish. Available from: http://www.gesida.seimc.org/pcientifica/dcconsensos.asp. Accessed May 30, 2012.
21. Cost of generic nevirapine in UK. Available from: http://www.unitedpharmacies-uk.com/Nevimune_Nevirapine_200mg_10_Tablets_p_369.html.
22. Ortiz R, DeJesus E, Khanlou H, et al. Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir-ritonavir in treatment naïve HIV-1 infected patients at Week 48. AIDS. 2008;22(12):1389-1397.
23. Molina J, Andrade-Villanueva J, Echeverria J, et al. Once-daily atazanavir-ritonavir compared with twice-daily lopinavir-ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1 infected patients: 96 week efficacy and safety results of the CASTLE study. J Acquir Immune Defic Syndr. 2009;53(3):323-332.
24. Gallant J, DeJesus E, Arribas J, et al. Tenofovir DF, emtricitabine and efavirenz vs zidovudine, lamivudine and efavirenz for HIV. N Engl J Med. 2006;354(3):251-260.
25. Moyle G, Sabin C, Cartledge J, et al. A randomised comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy. AIDS. 2006;20(16):2043-2050.
26. van Leth F, Phanuphak P, Ruxrungtham K, et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. Lancet. 2004;363(9417):1253-1263.
27. Soriano V, Arasteh K, Migrone H, et al. Nevirapine versus atazanavir/ritonavir each combined with tenofovir disoproxil fumarate/emtricitabine, in antiretroviral-naive HIV-1 patients: the ARTEN trial. Antivir Ther. 2011;16(3):2040-2058.
28. Arribas J, Clumeck N, Nelson M, et al. The MONET trial: week 144 analysis of efficacy of darunavir/ritonavir monotherapy versus DRV/r + 2NRTIs, for patients with HIV RNA, 50 copies/mL at baseline. Abstract MOPE215 presented at the 6th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, July 17-20, 2011, Rome, Italy.
29. Katlama C, Valentin MA, Algarte-Genin M, et al. Efficacy of darunavir/ritonavir as single-drug maintenance therapy in patients with HIV-1 viral suppression: a randomized open-label non-inferiority trial, MONOI-ANRS 136. AIDS. 2010;24(15):2365-2374.
30. Guaraldi G, Zona S, Cossarizza A, et al. Impact of switching to darunavir/ritonavir monotherapy vs triple-therapy on body fat redistribution and bone mass in virologically suppressed HIV-infected adults. The MONARCH randomized controlled trial. Abstract PE7.5/4 presented at the 13th European AIDS Conference, October 12-15, Belgrade, Serbia, 2011.
31. Gazzard B, Hill A, Anceau A. Cost-efficacy analysis of the MONET Trial using UK antiretroviral drug prices. Appl Health Econ Health Policy. 2011;9(4):217-223.
32. Bierman WF, van Agtmael MA, Nijhuis M, Danner SA, Boucher CA. HIV monotherapy with ritonavir-boosted protease inhibitors: a systematic review. AIDS. 2009;23(3):279-291.
33. UK Medical Research Council. A randomised controlled trial of a strategy of switching to boosted protease inhibitor monotherapy versus continuing combination antiretroviral therapy for the long-term management of HIV-1 infected patients who have achieved sustained virological suppression on highly-active antiretroviral therapy. Available from: http://www.controlled-trials.com/ISRCTN04857074. Accessed May 30, 2012.